Slide 1: Immunic Therapeutics Second Quarter 2023 Financial Results and Corporate Update
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21€ of the Securities
Slide 3: Agenda
Agenda Second Quarter 2023 Financial Results and Corporate Update 02 | Second Quarter 2023 and Subsequent Highlights 04 | Q&A Session Financial and Operating Results Summary and Highlights 03 | Anticipated Clinical Milestones 3 | © immunic, inc. | Aug/03/2023 & Immunic
Slide 4: Second Quarter 2023 and Subsequent Highlights
Slide 5: April: Positive Maintenance Phase Data of Phase CALDOSE-1 Trial
April: Positive Maintenance Phase Data of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis 30 mg of vidofludimus calcium found to be statistically superior to achieve clinical remission during maintenance Clinical Remission at Week 50 treatment at week 50 as c
Slide 6: April: Appointed Richard Rudick, M.D. to Board of Directors
6 April: Appointed Richard Rudick, M.D. to Board of Directors © immunic, inc. = Thought-leader in multiple sclerosis with decades of experience in the clinic, academia and industry = Effective April 26, 2023 & Immunic
Slide 7: May: Positive Results From Phase 1b Trial of IMU-856 in Celiac Disease
May: Positive Results From Phase 1b Trial of IMU-856 in Celiac Disease, Positive Effects in Main Four Dimensions of Clinical Outcome IMU-856 reduces/reverses gluten-induced symptoms reported by patients IMU-856 effectively reduces gluten-induced intestinal damage, as measured by villous height Impro
Slide 8: May: Presented Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023
May: Presented Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023 = May 6-9 in Chicago = Virtual e-poster: Franziska Buridnek, M.D., Senior Medical Director at Immunic — Data from the single and multiple ascending dose portions of the phase 1 clinical trial of IMU-856 in health
Slide 9: May: Published Preclinical Data Confirming Vidofludimus Calcium Acts as Nurr1 Activator
May: Published Preclinical Data Confirming That Vidofludimus Calcium Acts as a Potent Nurr1 Activator = Vidofludimus calcium induces a = Nurr1 is a transcription = Vidofludimus calcium enhances 5-fold activation, with an EC., of factor binding to DNA production of the Nurr1 target 440 nM concentrati
Slide 10: July: Hosted Virtual Celiac Disease Roundtable
Gimmie July: Hosted Virtual Celiac Disease Roundtable ‘Ongoing Active Celiac Disease and Its High Unmet Medical Need for New Treatment Options Immunic’s Virtual Celiac Disease KOL Roundtable ‘Thursday, July 20, 2023, 8:00 - 9:00 am Eastern Time Ongoing Active Celiac Disease and Its High Unmet Ee ORE
Slide 11: Financial and Operating Results
Slide 12: Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts, unaudited) Three Months ‘SixMonths Ended June 30, Ended June 30, 2023 2022 2023 2022 Operating expenses: Research and development $21,172] $ 16,538| $44,135) $33,983] General and administrative 3,849]
Slide 13: Anticipated Clinical Milestones
Slide 14: Several Clinical Value Inflection Points Expected
Several Clinical Value Inflection Points Expected Interim analysis phase 2 CALLIPER trial IMU-838 estimated for fall 2023 in PMS Readout phase 2 CALLIPER trial estimated for end of 2024 Interim analysis phase 3 ENSURE program IMU-838 estimated for late 2024 in RMS Readout of first phase 3 ENSURE tri
Slide 15: Q&A Session
Slide 16: Summary and Highlights
Slide 17: Advanced Clinical Pipeline
Advanced Clinical Pipeline Well Differentiated Programs in Various Phases of Clinical Development Program Preclinical Phase 1 Phase 2 Phase 3 Key Milestones Interim analysis of CALLIPER trial in Vidofludimus PMS planned after half of the Calcium patients completed 24 weeks of (imu-838) treatment, es
Slide 18: Thank You!
Thank You! Immunic, Inc. 1200 Avenue of the Americas New York City, NY 10036 USA Immunic AG Lochhamer Schlag 21 82166 Grifelfing (Munich) Germany Jessica Breu Head of IR & Communications & Phone: +49-89-2080477-09 & Email: ir@imux.com ® Web: www.imux.com Immunic Australia Pty. Ltd. Melbourne Austral